Medidata reaches into South Korea with a CRO partnership

Print 08 December 2015
Damian Garde / Fierce Biotech

South Korean CRO C&R Research is adopting Medidata's ($MDSO) eClinical technology for its trials throughout Asia, striking a partnership to bolster its data analysis technology in a fast-growing market.

Under the deal, C&R will implement Medidata's services for electronic data capture and risk-based monitoring for its work running studies around the region, a move the CRO said will help it speed up trial execution and cut costs for clients. C&R is adopting Medidata Rave, a cloud-based technology for gathering and storing patient data, and Medidata RBM, which allows the CRO to take a bird's-eye view of multiple sites to identify potential risks.

C&R, which bills itself as South Korea's first CRO, is working to stand out in a growing market, and bringing in Metadata's technology is its latest effort to burnish its offerings, company President Moon Tae Yoon said.

"South Korea has quickly become a key hub for multinational clinical trials, and we at C&R are committed to ensuring we support our local and global biopharmaceutical customers' R&D programs with the most innovative technologies," Yoon said in a statement.

The CRO got off the ground in 1997, gradually expanding across Asia and North America through partnerships with Oracle, INC Research ($INCR) and others. C&R's client roster boasts multinational pharma companies including GlaxoSmithKline ($GSK) and Novartis ($NVS).

Medidata has become an in-demand partner among the world's largest CROs, counting among its clients PPD, Icon ($ICLR), INC Research and Quintiles ($Q). The company's know-how in adaptive clinical trials also lured TransCelerate BioPharma, a consortium of the world's largest drugmakers, which recruited Medidata to help it convince its members to embrace risk-based monitoring.

Source

Return